Monural granules for oral solution, 3 g each, No. 1 per package
Composition
Active ingredient: fosfomycin;
1 packet contains 5.631 g of fosfomycin trometamol, equivalent to 3.0 g of fosfomycin;
Excipients: mandarin flavoring, orange flavoring, saccharin, sucrose.
Dosage Form
Granules for oral solution.
Main physical and chemical properties: a white granular powder with a characteristic mandarin scent.
Pharmacotherapeutic group
Antimicrobial agents for systemic use. Other antimicrobial agents. Fosfomycin.
ATC code J01X X01.
Pharmacological properties
Monural contains the active ingredient fosfomycin in the form of fosfomycin trometamol salt. Fosfomycin is a bactericidal antibiotic (a derivative of phosphonic acid). It inhibits bacterial cell wall synthesis by blocking one of the first steps in peptidoglycan synthesis.
Pharmacodynamics. Monural contains fosfomycin [mono(2-amino-2-hydroxymethyl-1,3-propanediol) (2R-cis)-(3-methyloxiranyl) phosphonate], an antibiotic derived from phosphonic acid and used to treat urinary tract infections.
Fosfomycin affects the first stage of bacterial cell wall synthesis.
The structure of fosfomycin is similar to that of phosphoenolpyruvate. This is why it inactivates the enzyme enolpyruvyltransferase, thereby irreversibly blocking the condensation of uridine diphosphate-N-acetylglucosamine with phosphoenolpyruvate, one of the first steps in bacterial cell wall synthesis. Fosfomycin may also reduce bacterial adhesion to the epithelial cells of the bladder mucosa, which may be a contributing factor to the development of recurrent infections.
The table below presents data on the in vitro activity of fosfomycin trometamol against clinically isolated organisms. The minimum inhibitory concentration (MIC) was determined by the disk-diffusion method using 200 μg phosphomycin trometamol disks. Microorganisms with a complete inhibition zone diameter > 16 mm (on Mueller-Hinton medium) were classified as susceptible (corresponding to 200 μg/mL).
| MIC90 (µg/mL) | Range | |
| Susceptible microorganisms | ||
| Escherichia coli | 8 | 0.25–128 |
| Klebsiella | 32 | 2–128 |
| Citrobacter spp. | 2 | 0.25–2 |
| Enterobacter spp. | 16 | 0.5–64 |
| Proteus mirabilis | 128 | 0.12–256 |
| S. faecalis | 60 | 8–256 |
| Resistant microorganisms (inhibition zone diameter
Complete inhibition > 16 mm) |
||
| Serratia spp. | 32 | |
| Enterobacter cloacae | 256 | |
| Pseudomonas aeruginosa | 256 | |
| Morganella morganii | >256 | |
| Providencia rettgeri | >256 | |
| Providencia stuartii | >256 | |
| Pseudomonas ssp. | >256 |
Resistance / Cross-Resistance
Fosfomycin remains effective against the most common bacteria found in urinary tract infections.
Only a few bacteria can develop resistance. The resistance rate of E. coli, which causes uncomplicated urinary tract infections, is extremely low.
Most multidrug-resistant E. coli and other enterobacteria that produce ESBLs (extended-spectrum beta-lactamases) are susceptible to fosfomycin. Similarly, most strains of methicillin-resistant Staphylococcus aureus are susceptible to fosfomycin.
To date, no cases of cross-resistance with other antibacterial agents have been reported. Cross-resistance is unlikely, as fosfomycin differs from any other antibiotic in its chemical structure and has a unique mechanism of action.
Clinical Efficacy
Fosfomycin has a broad spectrum of antibacterial activity, including most Gram-positive and Gram-negative microorganisms that cause urinary tract infections, as well as penicillinase-producing strains.
In vivo, resistance has been observed to Enterobacter spp., Klebsiella spp., Enterococci, Proteus mirabilis, Staphylococcus aureus, and saprophytic staphylococci.
In addition, Monural reduces bacterial adhesion to the bladder mucosal epithelium, which may be a contributing factor in the development of recurrent infections.
Pharmacokinetics.
Absorption
After oral administration, approximately 50% of fosfomycin trometamol is rapidly absorbed. Following oral administration at a dose of 50 mg/kg body weight, tmax is 2–2.5 hours, and C-PKC is 20–30 μg/mL.
Distribution
The plasma protein binding of fosfomycin is very low (less than 5%). The volume of distribution ranges from 1.5 to 2.4 L/kg of body weight.
Fosfomycin crosses the placental barrier and is excreted into breast milk.
Metabolism
Fosfomycin is not metabolized.
Excretion
The plasma half-life is approximately 4 hours. After a single dose of 3 g of fosfomycin trometamol, the concentration in urine ranges from 1,800 to 3,000 μg/mL within 2–4 hours. Therapeutically effective concentrations (200 to 300 μg/mL) persist for up to 48 hours after administration. Between 40% and 50% of the dose is excreted unchanged in the urine during the first 48 hours.
Pharmacokinetics in Specific Patient Populations
In patients with renal insufficiency, drug elimination is slowed depending on the degree of functional impairment, and the plasma half-life increases (t1/2 up to 50 hours at a creatinine clearance of 10 mL/min).
Indications
Treatment of acute, uncomplicated lower urinary tract infections caused by phosphomycin-susceptible microorganisms in men and girls aged 12 years and older, and in adult women. Prophylaxis during diagnostic procedures and surgical interventions in adult patients.
Contraindications
Hypersensitivity to the drug’s components, severe renal insufficiency (creatinine clearance < 10 mL/min), children under 12 years of age, hemodialysis.
Drug Interactions and Other Interactions
Concomitant use with metoclopramide and other drugs that increase gastrointestinal motility reduces the absorption of Monural, leading to lower concentrations of Monural in serum and urine.
Taking the medication with food reduces the level of fosfomycin in plasma and urine. Therefore, it is recommended to take the medication on an empty stomach or 2–3 hours after a meal or other medications.
Specific issues related to fluctuations in the INR (International Normalized Ratio). Numerous cases of increased antivitamin K activity have been reported in patients taking antibiotics. Risk factors include: serious infections or inflammation, advanced age, and poor overall health. In these cases, it is difficult to determine whether the change in INR is due to an infectious disease or caused by taking the medication. However, there are certain classes of antibiotics that are more frequently associated with fluctuations in the INR, such as fluoroquinolones, macrolides, cyclines, co-trimoxazole, and certain cephalosporins.
Interaction studies have been conducted only in adults.
Special Considerations for Use
There is insufficient evidence of Monural’s efficacy in children; since the 3-gram dosage is not intended for children under 12 years of age, Monural should not be used in this age group.
The use of fosfomycin may lead to hypersensitivity reactions, including anaphylaxis and anaphylactic shock, which can be life-threatening (see the “Side Effects” section).
If these reactions occur, treatment with fosfomycin should be discontinued; resuming fosfomycin in these patients is not permitted. Appropriate therapeutic measures must be taken.
Antibiotics, including fosfomycin trometamol, may cause antibiotic-associated diarrhea. The severity may range from mild diarrhea to fatal colitis. The onset of severe, persistent, and/or bloody diarrhea during or after (including several weeks after) the completion of antibiotic therapy may be a symptom of Clostridium difficile-associated diarrhea (CDAD). Therefore, this diagnosis should be considered in patients experiencing severe diarrhea during or after treatment with fosfomycin trometamol. If the diagnosis is suspected or confirmed, appropriate treatment should be initiated immediately. In this case, medications that inhibit peristalsis are contraindicated.
Renal insufficiency: The concentration of fosfomycin in urine remains therapeutically effective for 48 hours if creatinine clearance exceeds 10 mL/min.
Monural contains sucrose. Patients with diabetes and those on a restricted diet should be aware that one Monural packet contains 2.213 g of sucrose. Monural should not be used in patients with fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose-isomaltase deficiency.
Pregnancy and Lactation
Pregnancy
The use of single doses to treat urinary tract infections in pregnant women is not considered appropriate.
Animal studies have not revealed any direct or indirect toxicity affecting pregnancy, embryonic development, fetal development, and/or postnatal development.
Data on the safety of fosfomycin in pregnant women are limited. These data do not indicate the development of congenital defects or toxicity of fosfomycin to the fetus or newborn.
During pregnancy, the drug may be used if necessary, when the expected benefit of therapy for the pregnant woman outweighs the potential risk to the fetus.
Breastfeeding
Monural is excreted in breast milk even after a single dose. The drug should be discontinued during lactation.
Effects on the Ability to Drive and Operate Machinery
Monural may cause dizziness, which may affect the ability to drive or operate machinery.
Dosage and Administration
Monural is taken orally on an empty stomach, preferably before bedtime, after emptying the bladder. Dissolve the contents of the packet in 1 glass of water and drink the prepared solution immediately.
Taking the medication with food slows the absorption of fosfomycin. Therefore, it is recommended to take the medication on an empty stomach or 2–3 hours after a meal.
This dosage (3 g) is indicated for patients weighing 50 kg or more.
Treatment.
Adults and adolescents weighing 50 kg or more: 1 3-g Monural packet once daily.
Prevention
Adults weighing 50 kg or more: 1 packet of Monural 3 g 3 hours before and 24 hours after the procedure.
Children
May be used to treat acute, uncomplicated lower urinary tract infections in girls over 12 years of age.
There are insufficient data on the therapeutic use of the drug in boys over 12 years of age, as well as insufficient data on its prophylactic use in both boys and girls.
Overdose
Data on oral overdose with fosfomycin are limited.
Symptoms include vestibular disorders, hearing loss, a metallic taste in the mouth, and a general decrease in taste perception.
Cases of hypotension, severe drowsiness, electrolyte imbalances, thrombocytopenia, and hypoprothrombinemia have been reported with the use of parenteral fosfomycin.
Treatment: symptomatic and supportive care. It is recommended to drink plenty of fluids to increase urine output.
Side Effects
The most common adverse reactions following a single dose of fosfomycin trometamol include gastrointestinal disturbances, primarily diarrhea. These reactions are usually transient and resolve spontaneously.
The table below lists unexpected adverse reactions that were reported during clinical trials or identified through postmarketing experience.
The frequency of side effects is defined as follows:
very common (≥ 1/10);
common (≥ 1/100 – <1/10);
uncommon (≥ 1/1,000 – <1/100);
rare (≥ 1/100 – <1/1,000);
very rare (< 1/10,000);
Unknown (cannot be estimated from the available data).
Within each frequency group, adverse reactions are listed in descending order of severity.
| Organ system classes | Adverse Reactions and Frequency | |||
| Common | Uncommon | Rare | Unknown | |
| Infections and infestations | Vulvovaginitis | |||
| Immune System Disorders | Anaphylactic reactions, including anaphylactic shock, hypersensitivity | |||
| Nervous system disorders | Headache, dizziness | Paresthesia | ||
| Heart disorders | Tachycardia | |||
| Diseases of the respiratory system, chest, and mediastinum | Asthma | |||
| Digestive system disorders | Diarrhea, nausea, upset stomach | Vomiting, abdominal pain | Antibiotic-associated colitis | |
| Skin and subcutaneous tissue disorders | Rash, hives, itching | Angioedema | ||
| General disorders | Fatigue | |||
| Vascular disorders | Hypotension | |||
Reporting Adverse Reactions
It is important to report adverse reactions after a drug has been approved. This allows for continuous monitoring of the drug’s benefit-risk profile. Healthcare professionals are required to report any suspected adverse reactions through the national reporting system.
Shelf Life
3 years.
Storage Conditions
Store at a temperature not exceeding 30 °C. Keep out of the reach of children.
Packaging
8 g of the product (3 g of active ingredient) per sachet; 1 or 2 sachets per cardboard box.
.
Manufacturer
Zambo Switzerland Ltd.
Similar products
Products from the same category













